ImmunoPrecise Antibodies (NASDAQ:IPA) Posts Earnings Results, Hits Estimates

ImmunoPrecise Antibodies (NASDAQ:IPA) issued its earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06), Zacks reports. The business had revenue of $4.23 million for the quarter, compared to analyst estimates of $6.59 million. ImmunoPrecise Antibodies had a negative return on equity of 73.74% and a negative net margin of 114.50%.

ImmunoPrecise Antibodies Stock Performance

Shares of IPA stock opened at $0.39 on Friday. The stock’s 50-day moving average is $0.44 and its two-hundred day moving average is $0.48. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.85 and a current ratio of 1.01. ImmunoPrecise Antibodies has a 1 year low of $0.27 and a 1 year high of $1.59. The firm has a market cap of $12.18 million, a price-to-earnings ratio of -0.50 and a beta of 0.09.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of ImmunoPrecise Antibodies in a report on Friday, March 14th.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.